0

VX-745

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP209410468
CAS209410-46-8
Structure
MDL NumberMFCD09834070
Molecular Weight436.26
InChI KeyVEPKQEUBKLEPRA-UHFFFAOYSA-N
Description≥98% (HPLC)
SolubilityDMSO: 10 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditions−20°C
1

Activating β-catenin/Pax6 Axis Negatively Regulates Osteoclastogenesis by Selectively Inhibiting Phosphorylation of p38/MAPK

Zhiwei Jie, Shuying Shen, Xiangde Zhao, Wenbin Xu, Xuyang Zhang, Bao Huang, Pan Tang, An Qin, Shunwu Fan, Ziang Xie

FASEB J. 2019 Mar;33(3):4236-4247.

PMID: 30526042

1

Gram-scale Synthesis of the p38α MAPK-inhibitor VX-745 for Preclinical Studies Into Werner Syndrome

Mark C Bagley, Terence Davis, Matthew C Dix, Vincenzo Fusillo, Morgane Pigeaux, Michal J Rokicki, David Kipling

Future Med Chem. 2010 Sep;2(9):1417-27.

PMID: 21426137

1

Rapid Synthesis of VX-745: p38 MAP Kinase Inhibition in Werner Syndrome Cells

Mark C Bagley, Terence Davis, Matthew C Dix, Michal J Rokicki, David Kipling

Bioorg Med Chem Lett. 2007 Sep 15;17(18):5107-10.

PMID: 17659871

1

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor

John P Duffy, Edmund M Harrington, Francesco G Salituro, John E Cochran, Jeremy Green, Huai Gao, Guy W Bemis, Ghotas Evindar, Vincent P Galullo, Pamella J Ford, Ursula A Germann, Keith P Wilson, Steven F Bellon, etc.

ACS Med Chem Lett. 2011 Jul 28;2(10):758-63.

PMID: 24900264

1

VX-745. Vertex Pharmaceuticals

J J Haddad

Curr Opin Investig Drugs. 2001 Aug;2(8):1070-6.

PMID: 11892915

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode